Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Expands By 7.7%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 119,200 shares, an increase of 7.7% from the November 30th total of 110,700 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average daily volume of 33,100 shares, the short-interest ratio is currently 3.6 days.

Cyclo Therapeutics Trading Down 1.9 %

CYTH opened at $0.59 on Thursday. The stock has a market cap of $16.97 million, a price-to-earnings ratio of -0.66 and a beta of -0.46. Cyclo Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.12. The stock has a fifty day moving average price of $0.67 and a 200 day moving average price of $0.87.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.